US Patent

US7538116 — Treatment of sexual disorders

Method of Use · Assigned to Individual · Expires 2030-09-02 · 4y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating sexual dysfunction, including female sexual dysfunction, by administering gepirone hydrochloride.

USPTO Abstract

The present invention relates to a method of treatment of sexual dysfunction e.g. female sexual disfunction by administering to a person in need of treatment an effective amount of gepirone as either a short-term or a long-term therapy.

Drugs covered by this patent

gepirone-hydrochloride (GEPIRONE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3699`	—	gepirone-hydrochloride
`U-3699`	—	gepirone-hydrochloride
`U-3699`	—	gepirone-hydrochloride
`U-3699`	—	gepirone-hydrochloride

Patent Metadata

Patent number: US7538116
Jurisdiction: US
Classification: Method of Use
Expires: 2030-09-02
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.